Table 1.
Characteristics of included studies
|
Ref.
|
Treatment and sample size (n)
|
Baseline age (mean ± SD, median, range)
|
Treatment duration (mo)
|
Studying area
|
|
|
Intervention group
|
Control group
|
||||
| Zhang et al[12], 2020 | GLP-1RAs vs TZDs (30 vs 30) | 50.2 ± 11.5 | 51.5 ± 12.1 | 6 | China |
| Fan et al[33], 2013 | GLP-1RAs vs MET (49 vs 68) | 51.0 ± 10.1 | 54.7 ± 12.1 | 3 | China |
| Feng et al[28], 2017 | GLP-1RAs vs MET (29 vs 29) | 46.8 ± 9.7 | 46.3 ± 12.3 | 6 | China |
| Smits et al[34], 2016 | GLP-1RAs vs PLA (17 vs 17) | 60.8 ± 7.4 | 65.8 ± 5.8 | 3 | Netherlands |
| Armstrong et al[15], 2016 | GLP-1RAs vs PLA (26 vs 26) | 50.0 ± 11.0 | 52.0 ± 12.0 | 12 | United Kingdom |
| Hajiaghamohammadi et al[35], 2012 | MET vs TZDs (22 vs 22) | 32.6 ± 6.4 | 32.6 ± 6.4 | 2 | Iran |
| Razavizade et al[31], 2013 | MET vs TZDs (40 vs 40) | 36.4 ± 9.0 | 34.2 ± 6.8 | 4 | Iran |
| Shargorodsky et al[36], 2012 | MET vs PLA (32 vs 31) | 51.9 ± 10.9 | 55.2 ± 14.0 | 4 | Israel |
| Kazemi et al[37], 2011 | MET vs PLA (18 vs 15) | 41.5 (25-58) | 43.5 (26-62) | 6 | Iran |
| Haukeland et al[30], 2009 | MET vs PLA (20 vs 24) | 44.3 ± 9.0 | 49.9 ± 12.8 | 6 | Norway |
| Omer et al[29], 2010 | MET vs TZDs (22 vs 20) | 48.0 ± 9.8 | 49.3 ± 6.0 | 12 | Turkey |
| Anushiravani et al[38], 2019 | MET vs TZDs (30 vs 30) | NA | NA | 3 | Iran |
| Ito et al[9], 2017 | SGLT2 vs TZDs (32 vs 34) | 57.3 ± 12.1 | 59.1 ± 9.8 | 6 | Japan |
| Kinoshita et al[26], 2020 | SGLT2 vs TZDs (32 vs 33) | 58.7 ± 9.1 | 59.0 ± 10.9 | 7 | Japan |
| Eriksson et al[39], 2018 | SGLT2 vs PLA (21 vs 21) | 65.0 ± 6.5 | 65.6 ± 6.1 | 3 | Sweden |
| Chehrehgosha et al[8], 2021 | SGLT2 vs TZDs (35 vs 34) | 50.5 ± 8.4 | 52.5 ± 7.9 | 6 | Iran |
| Yoneda et al[27], 2021 | TZDs vs SGLT2 (19 vs 21) | 58.8 ± 8.1 | 58.4 ± 12.2 | 6 | Japan |
| Belfort et al[6], 2006 | TZDs vs PLA (26 vs 21) | 51.0 ± 7.0 | 51.0 ± 10.0 | 6 | United States |
| Ratziu et al[40], 2008 | TZDs vs PLA (32 vs 31) | 53.1 ± 11.5 | 54.1 ± 10.4 | 12 | France |
| Cusi et al[41], 2016 | TZDs vs PLA (50 vs 51) | 52.0 ± 10.0 | 49.0 ± 11.0 | 18 | United States |
| Sanyal et al[42], 2010 | TZDs vs PLA (80 vs 83) | 47.0 ± 12.6 | 45.4 ± 11.2 | 24 | United States |
| Aithal et al[43], 2008 | TZDs vs PLA (37 vs 37) | 55 (27-73) | 52 (28-71) | 12 | United Kingdom |
GLP-1RAs: Glucagon-like peptide-1 receptor agonists; TZDs: Thiazolidinediones; MET: Metformin; SGLT2: Sodium glucose co-transporter-2; PLA: Placebo.